Beta Bionics (NASDAQ:BBNX) Cut to Strong Sell at Wall Street Zen

Wall Street Zen downgraded shares of Beta Bionics (NASDAQ:BBNX) from a hold rating to a strong sell rating in a research note published on Saturday morning,Wall Street Zen reports.

Several other equities analysts also recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Beta Bionics in a report on Monday, October 12th. They set a “buy” rating and a $30.00 price target for the company. Barclays started coverage on shares of Beta Bionics in a research note on Tuesday, October 6th. They set an “overweight” rating and a $30.00 price objective on the stock. Bank of America upped their price objective on shares of Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 15th. Weiss Ratings raised shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Finally, Wells Fargo & Company initiated coverage on shares of Beta Bionics in a research note on Wednesday, September 23rd. They issued an “overweight” rating and a $28.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.69.

Beta Bionics Stock Performance

Shares of NASDAQ:BBNX opened at $15.90 on Friday. Beta Bionics has a 52 week low of $8.80 and a 52 week high of $32.71. The company’s fifty day moving average is $19.04 and its 200-day moving average is $14.88. The company has a market capitalization of $864.44 million, a PE ratio of -8.64 and a beta of 3.39.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Tuesday, October 27th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.01. The business had revenue of $35.51 million for the quarter. Beta Bionics had a negative net margin of 65.31% and a negative return on equity of 27.33%. On average, analysts forecast that Beta Bionics will post -2.03 EPS for the current year.

Insider Activity at Beta Bionics

In related news, insider Steven Russell sold 4,221 shares of Beta Bionics stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $80,663.31. Following the completion of the transaction, the insider directly owned 169,628 shares of the company’s stock, valued at $3,241,591.08. The trade was a 2.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Stephen Feider sold 6,675 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $127,559.25. Following the transaction, the chief financial officer owned 159,378 shares in the company, valued at approximately $3,045,713.58. This trade represents a 4.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 101,943 shares of company stock valued at $1,995,201. 5.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Beta Bionics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BBNX. Legal & General Group Plc acquired a new position in shares of Beta Bionics during the second quarter worth approximately $62,000. Commonwealth Equity Services LLC grew its stake in shares of Beta Bionics by 34.7% during the third quarter. Commonwealth Equity Services LLC now owns 31,795 shares of the company’s stock valued at $603,000 after purchasing an additional 8,196 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Beta Bionics in the second quarter valued at approximately $172,000. Ieq Capital LLC acquired a new stake in shares of Beta Bionics in the second quarter valued at approximately $229,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Beta Bionics in the second quarter valued at approximately $264,000.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics’ earnings-call coverage highlighted a major regulatory clearance for its product and record growth, developments that could support broader commercialization and revenue expansion. Beta Bionics Earnings Call: Mint Clearance Fuels Growth
• Neutral Sentiment: Multiple law firms reminded investors that November 3, 2026 is the deadline to seek lead-plaintiff status in a federal securities class action covering purchases of BBNX stock from July 30, 2025, through February 24, 2026. The notices primarily seek potential plaintiffs and do not establish liability or investor compensation. Hagens Berman BBNX Deadline Alert
• Negative Sentiment: The complaints reportedly allege that Beta Bionics failed to disclose material adverse information, including a June 2025 FDA Form 483 that allegedly cited more than 18,000 unreported complaints involving the company’s iLet product. The lawsuit also names senior executives in connection with certifications of SEC filings. These are allegations, but the potential regulatory-disclosure issues increase litigation, reputational and financial risk for BBNX. Levi and Korsinsky BBNX Class Action Notice

About Beta Bionics

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.